Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:31 AM ET 8-K
Leadership Change MongoDB, Inc. MDB

MongoDB Leadership Change

Chirantan “CJ” Desai has resigned as President and CEO of MongoDB to pursue a senior role at Meta Platforms, Inc. The Board has appointed former CEO Dev Ittycheria as Interim President and CEO while it initiates a search for a permanent successor. The company also reaffirmed its previously issued financial guidance for Q3 and full year fiscal 2027.

8:30 AM ET Form 4
Insider Buying Anixa Biosciences Inc ANIX

Anixa Biosciences Insider Arnold M. Baskies Buys $13.8K of Stock

Arnold M. Baskies bought 5,000 shares of Anixa Biosciences Inc at $2.76 a share, worth $13.8K in total on Sep 24, 2026. Shares held after the trade: 140,572 (+3.7%).

Value
$13.8K
Shares
5,000
Price
$2.76
Holding change
+3.7%
Trade date
Sep 24, 2026
8:23 AM ET 8-K
Business Update DeFi Development Corp. DFDV

DeFi Development Business Update

DeFi Development Corp. reported a 2% weekly increase in its Solana (SOL) treasury holdings, reaching a total of 2,538,010 SOL and SOL equivalents valued at approximately $309 million. The company has grown its SOL treasury by 10% since its August 12 earnings update and intends to deploy these assets through staking and validator infrastructure to support its 'Digital Credit 2.0' strategy.

8:20 AM ET 8-K
Loan & Debt Skydance Corp SKYD

Paramount Skydance $44.4B Debt Financing

Paramount Skydance Corporation announced a massive $44.4 billion offering of senior secured first and second lien notes to finance its pending acquisition of Warner Bros. Discovery. The debt package includes both U.S. dollar and euro-denominated notes and is intended to fund the purchase price and repay existing debt. The offering is part of a broader permanent financing plan that includes previously announced term loans and equity financing.

Value
$44.4B
8:18 AM ET 8-K
Deal Termination Cycurion, Inc. CYCU

Cycurion Deal Termination with Yield Point NY LLC

Cycurion, Inc. has terminated its Equity Purchase Agreement with Yield Point NY LLC for convenience, effective September 26, 2026. The company also provided a business update forecasting $843,028 in 2026 revenue from public safety engagements in Chicago and noted it is still awaiting a final delisting decision from the Nasdaq Hearings Panel.

Counterparty
Yield Point NY LLC
8:17 AM ET 8-K
M&A Deal Bold Eagle Acquisition Corp. BEAG

Bold Eagle Acquisition Signs $1.25B M&A Deal with REDLattice

Bold Eagle Acquisition Corp. (BEAG) has entered into a definitive business combination agreement to acquire REDLattice, a cyber intelligence platform for defense and national security, at a pre-money enterprise value of $1.25 billion. The transaction is supported by $335 million in committed capital, including a $60 million common stock investment, and will result in REDLattice becoming a publicly traded company on the Nasdaq under the ticker 'REDL'.

Value
$1.25B
Counterparty
REDLattice (REDL Intermediate Holdings, LLC)
8:17 AM ET 8-K
Clinical Trial Data Transcode Therapeutics, Inc. RNAZ

Transcode Therapeutics Clinical Trial Data

TransCode Therapeutics announced updated Phase 1a clinical trial data for TTX-MC138, showing a 71.4% stable disease rate in patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities reported, and three patients remained progression-free at the one-year mark. The company believes the durability of disease control warrants continued clinical evaluation of the RNA-based therapeutic candidate.

8:16 AM ET 8-K
Clinical Trial Data Adicet Bio, Inc. ACET

Adicet Bio Clinical Trial Data

Adicet Bio announced positive preliminary Phase 1 data for prula-cel in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing a 50% complete renal response rate and 54% DORIS remission at 12 months. The therapy was generally well tolerated with no Grade 3 or higher CRS and no ICANS, supporting potential outpatient administration. Based on these results, the company plans to initiate pivotal trial start-up activities in the fourth quarter of 2026.

Earnings call
Sep 28, 2026, 8:00 AM ET
8:11 AM ET 8-K
Business Update Fate Therapeutics Inc FATE

Fate Therapeutics Business Update

Fate Therapeutics was awarded a $15 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 RECLAIM-LN clinical trial. The funding will advance the development of FT819, an off-the-shelf CAR T-cell therapy for patients with refractory lupus nephritis, a severe manifestation of systemic lupus erythematosus.

Counterparty
California Institute for Regenerative Medicine (CIRM)
8:06 AM ET 8-K
Contract Win Volato Group, Inc. SOAR

Volato Group Wins $1.17B Contract from a large AI customer

Volato Group's subsidiary, Alignment Engine, signed a Master Services Agreement and two initial orders with a large AI customer for dedicated AMD GPU infrastructure in Ohio. The aggregate contract value is approximately $1.17 billion over a four-year take-or-pay term, including $133 million in contractual prepayments. This represents a transformational milestone for the company's AI infrastructure platform.

Value
$1.17B
Counterparty
a large AI customer
Term
48-month term
8:06 AM ET 8-K
Clinical Trial Data 4D Molecular Therapeutics, Inc. FDMT

4D Molecular Therapeutics Clinical Trial Data

4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.

8:04 AM ET 8-K
Regulatory Approval Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Regulatory Approval

The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. The drug, licensed from Incyte, is a first-of-its-kind oral ALK2 inhibitor designed to reduce new heterotopic ossification (abnormal bone formation). Mirum expects the product to be commercially available in the U.S. in October 2026.

Counterparty
Incyte Corporation
8:02 AM ET 8-K
Licensing Deal Ainos, Inc. AIMD

Ainos Licensing Deal with BioPhoenix Co., Ltd. Worth $10M

Ainos entered into a global exclusive license agreement with BioPhoenix for its VELDONA low-dose oral interferon alpha technology platform for Sjögren’s Disease and Thrombocytopenia. Ainos will receive an upfront fee of $600,000 and is eligible for up to $10.0 million in total fees if additional indications are licensed, plus 25% of net sublicensing revenue. BioPhoenix will assume all clinical and regulatory funding and execution for the licensed indications.

Value
$10M
Counterparty
BioPhoenix Co., Ltd.
Term
20 years
8:02 AM ET 8-K
Clinical Trial Data Keros Therapeutics, Inc. KROS

Keros Therapeutics Clinical Trial Data

Keros Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial evaluating rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). The open-label, multi-cohort trial will assess safety, tolerability, and functional improvements in ambulatory and non-ambulatory patients, with initial data expected in the first half of 2027.

8:02 AM ET 8-K
Reverse Stock Split SHF Holdings, Inc. SHFS

SHF Holdings Reverse Stock Split

SHF Holdings (Safe Harbor Financial) has approved a 1-for-12 reverse stock split of its common stock, effective September 30, 2026. The split aims to consolidate every twelve outstanding shares into one share to adjust the trading price on the Nasdaq Stock Market. Stockholders previously approved the measure at a special meeting held in November 2025.

8:02 AM ET 8-K
Reverse Stock Split Matinas BioPharma Holdings, Inc. MTNB

Matinas BioPharma Holdings Reverse Stock Split

Matinas BioPharma implemented a one-for-fifteen (1:15) reverse stock split of its common stock effective September 28, 2026. The split was previously approved by stockholders at the 2025 annual meeting and is intended to adjust the share price for continued trading on the NYSE American.

8:02 AM ET 8-K
Capital Raise Strategy Inc MSTR

Strategy Capital Raise of $246M

Strategy Inc raised $246.2 million in net proceeds through the sale of 1,469,165 shares of Class A Common Stock under its at-the-market (ATM) offering program between September 21 and September 27, 2026. The company utilized $142.7 million of the proceeds to purchase 1,665 additional bitcoins and $103.5 million to fund repurchases of its STRC preferred stock. As of September 27, 2026, the company held a total of 847,666 bitcoins acquired at an aggregate purchase price of approximately $63.95 billion.

Value
$246M
8:02 AM ET 8-K
Business Update Strive, Inc. ASST

Strive Business Update

Strive, Inc. provided an operational update disclosing the purchase of 1,107 bitcoin between September 21 and September 25, 2026, at an average price of $85,396 per token. The company also reported updated treasury holdings, showing a total of 27,462 bitcoin and $248.8 million in cash and cash equivalents as of September 25, 2026.

8:02 AM ET 8-K
M&A Deal Lakeshore Acquisition III Corp. LCCC

Lakeshore Acquisition III M&A Deal with CPRO Electronics Co. Ltd.

Lakeshore Acquisition III Corp. has extended the deadline to complete its initial business combination from October 1, 2026, to November 1, 2026. The extension was triggered by a $67,500 payment into the company's trust account by its merger partner, CPRO Electronics Co. Ltd., pursuant to their existing merger agreement.

Counterparty
CPRO Electronics Co. Ltd.
Term
1 month
7:55 AM ET Form 4
Insider Selling Qfin Holdings, Inc. QFIN

Qfin Holdings Insider Andrew Y. Yan Sells $4.89M of Stock

Andrew Y. Yan sold 656,700 shares of Qfin Holdings, Inc. at $7.36 to $7.52 a share (average $7.44) in 2 transactions, worth $4.89M in total between Sep 24, 2026 and Sep 25, 2026. Shares held after the trade: 0 (-100.0%).

Value
$4.89M
Shares
656,700
Average price
$7.44
Holding change
-100.0%
Trade date
Sep 24, 2026 to Sep 25, 2026
7:43 AM ET 8-K
M&A Deal TransDigm Group INC TDG

TransDigm Group Signs $1.07B M&A Deal with Prince & Izant

TransDigm Group completed the acquisition of Prince & Izant, a manufacturer of highly engineered brazing alloys and specialty metal components, for approximately $1.066 billion in cash. The acquisition, financed with cash on hand, expands TransDigm's presence in the aerospace and defense aftermarket and is expected to generate $390 million in revenue for calendar year 2026.

Value
$1.07B
Counterparty
Prince & Izant
7:42 AM ET 8-K
Stock Buyback News Corp NWSA

News Announces $1B Stock Buyback

News Corp provided a daily update on its $1 billion stock repurchase program as required by Australian Securities Exchange (ASX) rules. The program authorizes the company to buy back outstanding shares of both Class A and Class B common stock from time to time in the open market. This filing specifically reports daily transaction activity for Class A common stock under the 2025 Repurchase Program.

Value
$1B
7:38 AM ET 8-K
M&A Deal Valley National Bancorp VLY

Valley National Bancorp Signs $340M M&A Deal with Bluevine Inc.

Valley National Bancorp (VLY) has entered into a definitive agreement to acquire Bluevine Inc., a digital banking platform for small businesses, for approximately $340 million. The deal consists of $255 million in cash and approximately 6.3 million shares of Valley common stock, aimed at enhancing Valley's core funding base and accelerating its digital and AI strategy. Bluevine brings approximately $2.1 billion in low-cost deposits and 175,000 active small business customers to the combined organization.

Value
$340M
Counterparty
Bluevine Inc.
Earnings call
Sep 28, 2026, 8:30 AM ET
7:32 AM ET 8-K
Partnership Soluna Holdings, Inc SLNH

Soluna Holdings Partnership with Bitdeer Technologies Group

Soluna Holdings expanded its co-mining partnership with Bitdeer Technologies Group to deploy an additional 7 MW of Bitcoin mining equipment at its Project Kati 1 site in Texas. This amendment brings Bitdeer's total deployment at the site to 35 MW (approximately 2.42 EH/s), fully subscribing the site's K1BC phase under a revenue-sharing structure.

Counterparty
Bitdeer Technologies Group
7:32 AM ET 8-K
Court & Legal Update Ramaco Resources, Inc. METC

Ramaco Resources Court & Legal Update

A federal jury in West Virginia awarded Ramaco Resources $30 million in damages following a retrial regarding the wrongful denial of an insurance claim related to a 2018 silo failure. The award includes $27.5 million for net economic loss and $2.5 million for aggravation and inconvenience, with a final determination on attorney's fees still pending from the Court.

Counterparty
Federal Insurance Company and ACE American Insurance Company (Chubb)
7:32 AM ET 8-K
Loan & Debt Hut 8 Corp. HUT

Hut 8 $1.07B Debt Financing with JPMorgan Chase Bank, N.A.

Hut 8 Corp. entered into a $1.07 billion senior secured revolving credit facility with a syndicate of lenders led by JPMorgan Chase Bank. The facility includes a $1.07 billion letter of credit sublimit and is intended to provide non-dilutive liquidity for general corporate purposes and to support collateral requirements for AI data center development.

Value
$1.07B
Counterparty
JPMorgan Chase Bank, N.A.
Term
4 years
7:16 AM ET 8-K
Product Launch Eton Pharmaceuticals, Inc. ETON

Eton Pharmaceuticals Product Launch

Eton Pharmaceuticals has launched IMPAVIDO (miltefosine) capsules in the United States for the treatment of visceral, cutaneous, and mucosal leishmaniasis. The company has integrated the product into its Eton Cares rare disease commercial infrastructure, providing patient support services and centralized distribution through Anovo Specialty Pharmacy.

7:03 AM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced the peer-reviewed publication of a pooled cardiac safety analysis of its drug candidate Annamycin in Frontiers in Cardiovascular Medicine. The analysis of 90 patients across five clinical trials found no clinical or subclinical evidence of cardiotoxicity, even at cumulative doses exceeding traditional anthracycline limits.

Counterparty
Cleveland Clinic

“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program. For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin
7:03 AM ET 8-K
Business Update Flutter Entertainment plc FLUT

Flutter Entertainment Business Update

Flutter Entertainment has ceased its sports betting and iGaming operations in Brazil following a provisional executive order from the Brazilian Government banning such activities. The company expects this cessation to reduce its 2026 revenue by approximately $70 million and adjusted EBITDA by $20 million if operations remain suspended for the rest of the year.

Counterparty
Brazilian Government

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.